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Introduction:
Malignant transformation of cells is characterized by the accumulation of mutations that allow the tumor cells to circumvent growth constraints, inter alia by acquisition of apoptosis resistance. Stress situation like hypoxia, DNA damage, growth factor withdrawal, and chemotherapeutic agents initiate the intrinsic apoptotic pathway which ultimately results in the release of cytochrome C from the mitochondria into the cytosol where caspases become activated to execute apoptosis [1] [2] [3] [4] .
Members of the Bcl-2 protein family which act at the mitochondrial level regulating mitochondrial homeostasis and permeability are important modulators of the intrinsic apoptotic pathway and other events, e.g. autophagy and necrosis [5] [6] [7] . The Bcl-2 protein family consists of various pro-and anti-apoptotic members that form heterodimers in order to inhibit or activate each other. The anti-apoptotic members comprise the well-known proteins Bcl-2 and Bcl-xL as well as Bcl-w, Mcl-1, A1, and Boo/Diva and are often upregulated in tumors. The pro-apoptotic members include the multi-domain proteins Bak, Bax, and Bok, and the very heterogeneous group of so-called "BH3-only proteins" (Bid, Bim Bad, Bmf, Bik, Hrk, Noxa) that have only one small stretch of amino acids in common and are suggested to constitute intracellular sensors of cellular stress.
Activation of the multidomain proteins Bax or Bak or even both is absolutely required for the initiation of the intrinsic apoptotic pathway. Currently two main models have been proposed to explain how Bcl-2 members might promote mitochondrial permeabilization and subsequent apoptosis. The displacement model or indirect activation model is based on the notion that anti-apoptotic Bcl-2 proteins directly interact with Bax and Bak to suppress their activation in healthy cells [5, 6, 8] . In response to apoptotic stimuli, specific BH3-only proteins become activated, bind to their respective anti-apoptotic counterparts, and displace them from their interaction with Bax and Bak. Unbound Bax and Bak undergo spontaneous selfoligomerization facilitating the breakdown of the mitochondrial membrane potential (ΔΨm), cytochrome C release into the cytosol, caspase-activation, and finally apoptosis.
In contrast, the direct activation model subdivides the BH-3 only proteins into so-called "sensitizers" (Bad, Bmf, Bik, Hrk, Noxa) that bind to anti-apoptotic Bcl-2 family members and the "activators" (t-Bid, Bim, Puma) that are suggested to bind directly to the proapoptotic multi-domain proteins Bax and Bak thereby triggering their activation. This model is supported by the observation that tBid, Bim, and possibly also Puma are required to activate Bax and Bak in order to induce apoptosis [9] [10] [11] [12] . In healthy cells the anti-apoptotic Bcl-2 proteins keep the activator BH3-only proteins in check unless apoptotic stimuli lead to the A c c e p t e d M a n u s c r i p t 4 accumulation of active sensitizer BH3-only proteins that displace the activator BH3-only proteins from their binding partners which then bind to and activate Bax and/or Bak.
Although initial publications suggested a redundant role for the members of the three main groups of Bcl-2 proteins, recent results implicate that particularly BH3-only proteins may be regulated by specific cellular stress signals. Moreover, protein interaction studies have shown that certain BH3-only proteins favor the interaction with specific anti-apoptotic family members supporting the hypothesis of non-redundant but specific action of the BH3-only protein members [6, 13] .
The non-steroidal anti-inflammatory drug Celecoxib is known as a specific inhibitor of cyclooxygenase-2 (COX-2). Surprisingly, Celecoxib and its derivates turned out to exert promising anti-neoplastic effects that may be exploited in cancer prevention and treatment [14] . Cyclooxygenases catalyze the conversion of arachidonic acid into prostaglandins and are major players during the process of inflammation [15] . COX-2 overexpression is observed in many human tumors and contributes to tumorigenesis and therapy resistance. Therefore, the anti-neoplastic activity of Celecoxib had first been related to its inhibitory action on COX-2.
Recent experiments in COX-2 negative cell lines, however, showed that Celecoxib is able to inhibit proliferation and induce apoptosis in a COX-2-independent manner. This observation was corroborated by similar findings in experiments performed with cells in which COX-2 was knocked down by siRNA or by the use of Celecoxib derivatives without COX-2 inhibitory action [16] [17] [18] [19] .
We and others have shown earlier that Celecoxib induced apoptosis through activation of an intrinsic pathway that was not blocked by overexpression of Bcl-2 [20] [21] [22] [23] . Moreover, we recently demonstrated that in Bax-deficient Jurkat cells Bak was essential for Celecoxibinduced apoptosis [17] . Aim of the present investigation was to specify pro-and anti- 
Reagents and antibodies
All chemicals were purchased from Sigma (Deisenhofen, Germany) unless otherwise specified.
For Western blotting following antibodies were used: polyclonal antibodies against caspase-3, PARP, Mcl-1, Bcl-xL, and α/β-Tubulin were obtained from Cell Signaling (NEB Frankfurt, Germany). The monoclonal antibody against Bcl-2 from Santa Cruz Biotechnology (clone 100, Heidelberg, Germany), the monoclonal caspase-9 antibody and the polyclonal Bak antibody from Upstate (Millipore, Schwalbach, Germany). COX-2 and cytochrome C (clone 7H8.2C12) monoclonal antibodies were obtained from Transduction Labs (Becton Dickinson, Heidelberg, Germany). Noxa monoclonal antibody was purchased from Calbiochem (Merck, Nottingham, UK). The monoclonal antibody against β-Actin was obtained from Sigma (Deisenhofen, Germany), the monoclonal antibody against GAPDH from Abcam (Cambridge, UK). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from GE Healthcare/Amersham Biosciences (Freiburg, Germany).
Bak activation was determined using the activation-specific antibody from Calbiochem (Merck, Nottingham, UK) or the matched IgG control from Santa Cruz Biotechnology, Heidelberg, Germany) in combination with Alexa488-coupled anti-mouse antibody from Molecular Probes (Invitrogen, Karlsruhe, Germany).
Immunoprecipitation was performed with a monoclonal antibody against Mcl-1 (Becton Dickinson, Heidelberg, Germany) or Noxa (Calbiochem/Merck, Nottingham, UK).
The pan-caspase inhibitor zVAD-fmk was purchased from Bachem (Bubendorf, Suisse).
Celecoxib was kindly provided by Pharmacia-Pfizer (Erlangen, Germany).
Cells and cell culture
Jurkat E6 T-lymphoma cells were from ATCC (Bethesda, Maryland, USA). Jurkat cells stably expressing Bcl-xL or Bcl-2 and the respective Vector control were prepared as described before [1, 24] .
Cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (Gibco Life Technologies, Eggenstein, Germany) and maintained in a humidified incubator at 37°C and 5% CO 2 .
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Transfection with siRNA
Cells were cultured at a low density to ensure log phase growth. For transfection 2x10 6 Immediately after transfection cells were resuspended in 6 mL prewarmed medium and continued to be cultured as described above. Transfection efficiency and viability was determined by transfecting the cells with 400 nM green fluorescence siRNA (siGLO from Dharmacon, Chicago, IL, USA) followed by propidium iodide exclusion dye and flow cytometric analysis.
Determination of apoptosis and necrosis by fluorescence microscopy
Morphological changes during apoptosis like chromatin condensation and permeability of the plasma membrane were analyzed by fluorescence microscopy after co-staining the cells with 
Flow cytometric analysis
The mitochondrial membrane potential (ΔΨm) was analyzed using the ΔΨm specific dye TMRE (Molecular Probes, Mobitech, Goettingen, Germany). At the indicated time points 10 5 cells were stained for 30 min in PBS containing 25 nM TMRE. Co-incubation with 1 µM of the cyanide derivate CCCP was used as a positive control to complete the mitochondrial depolarisation.
Nuclear fragmentation was determined after staining the cells with 5 µg/mL propidium iodide in a hypotonic buffer containing 0.1% sodium citrate and 0.1% Triton X-100 for 1 h at room temperature.
M a n u s c r i p t All Western blot experiments were repeated at least twice. 
Cytochrome c release

Immunoprecipitation
Cells were lysed as described above. The protein concentration was adjusted to 1 mg/mL.
5 µg antibody and 50 µL slurry Dynabeads suspension (Dynal/Invitrogen, Karlsruhe, Germany) were added to 500 µL lysate. After the precipitation for 3h at 4°C the beads were washed thrice with 300 µL lysis buffer containing 0.2% CHAPS. Proteins were eluted by boiling the beads for 5 min in 100 µL SDS sample buffer with β-Mercaptoethanol. 30 µL were separated by SDS gel electrophoresis before detection by Western blotting as described above.
M a n u s c r i p t
Results:
Celecoxib-induced apoptosis involves activation of Bak
Our earlier data revealed that in Jurkat T-lymphoma cell lines pro-apoptotic Bak was required for apoptosis induction in response to treatment with Celecoxib [17] . indicating that Bak activation and mitochondrial permeabilization occur upstream of caspase activation.
Celecoxib signals through the Mcl-1/Noxa axis
Activation of the multidomain proteins Bak or Bax or even both is absolutely required for the initiation of mitochondrial permeabilization, a key event in the intrinsic apoptosis pathway. (Fig. 3C) . However, when treated with 75 µM Celecoxib, sensitivity of Jurkat E6.1 cells to Celecoxib-induced apoptosis was significantly reduced by Noxa silencing as measured by DNA fragmentation (Fig. 3D ).
These data reveal for the first time that Noxa functions as a central mediator of Celecoxibinduced apoptosis. 
Overexpression of Bcl-xL but not Bcl-2 interferes with Celecoxib-induced apoptosis in Jurkat T lymphoma cells
Up to now our data pointed to a central role of the Mcl-1/Noxa axis for Bak-dependent apoptosis induction in response to treatment with Celecoxib. However, previous publications suggested that, apart from Mcl-1, Bcl-xL is an additional factor controlling Bak activation.
To clarify a putative role of Bcl-xL and Bcl-2 in the regulation of Bak-dependent apoptosis, Bcl-xL overexpression, however, was very protective against Celecoxib-induced cell death.
Consistent with these data, Bcl-xL overexpression also suppressed Bak activation (Fig. 4E) , release of cytochrome C into the cytosol (Fig. 4F ), ΔΨm breakdown (Fig. 4C) , as well as processing of caspase-9, caspase-3, and PARP cleavage (Fig. 4D ) in response to Celecoxib, whereas overexpression of the very similar Bcl-2 hardly affected any of these events.
Interestingly, despite its strong protective effects against the cytotoxic action of Celecoxib, Bcl-xL did not prevent the downregulation of Mcl-1. Fig. 5C ).
Neutralization of both Mcl-1 and Bcl-xL is neccessary for successful induction of apoptosis in Bcl-xL overexpressing Jurkat cells
Up to now our data indicated that although overexpression of Bcl-2 or Bcl-xL protected Jurkat cells efficiently from apoptosis induction by siRNA-mediated Mcl-1 silencing, only
Bcl-xL overexpression protected from mitochondrial damage and nuclear fragmentation induced by Celecoxib. Therefore, in a last set of experiments, it remained to be determined whether silencing of Bcl-xL would render the Bcl-xL overexpressing cells sensitive to treatment with Celecoxib again. To this end, Bcl-xL overexpressing and Vector control cells were transfected with bcl-x siRNA before analyzing DNA fragmentation (Fig. 6A) . Although silencing of Bcl-xL itself slightly induced apoptosis in Jurkat Vector cells within 72h after electroporation, the apoptotic rates never reached those obtained in response to Mcl-1 silencing (Fig. 6A, upper panel) . In Bcl-xL overexpressing Jurkat cells, Bcl-xL expression was clearly downregulated already 24h after electroporation (Fig. 6B) . Nevertheless, silencing of Bcl-xL did not induce apoptosis on its own (Fig. 6A, lower panel) . However, silencing of Bcl-xL restores the sensitivity towards apoptosis induced by Celecoxib (Fig. 6C) . In an additional experiment, 48h after first electroporation with bcl-x siRNA (1st EP), the cells M a n u s c r i p t 14 were electroporated a second time with mcl-1 siRNA or the non-targeting control siRNA (2nd EP). Consistently, siRNA-mediated Mcl-1 silencing induced ΔΨm breakdown and apoptosis in Bcl-xL-silenced cells (Fig. 6E ). Successful downregulation of appropriate proteins was verified by Western blotting (Fig. 6D and F) . We conclude that, in Bcl-xL overexpressing cells, the execution of apoptosis by Celecoxib or Mcl-1 silencing is only possible when both,
Mcl-1 and Bcl-xL are neutralized.
Discussion:
Apart from its anti-inflammatory action, the selective COX-2 inhibitor Celecoxib exerts potent anti-tumor effects. Consequently, the drug found application in cancer prevention in patients with familial adenomatous polyposis. Here, we showed that Celecoxib effectively induces apoptosis in Bax-deficient COX-2-negative Jurkat T lymphoma cells. Moreover, we demonstrate for the first time that Celecoxib-induced apoptosis involves the Mcl-1/Noxa axis and can be efficiently blocked by overexpression of Bcl-xL but not the similar Bcl-2.
In camptothecin, the cyclin-dependent kinase inhibitor Seliciclib, the proteasome inhibitor bortezomib, histone deacetylsae inhibitors, arsenic trioxide, and glucose withdrawal [28] [29] [30] [31] [32] [33] .
The BH3-only protein Noxa belongs to the group of sensitizers that do not activate Bax or
Bak by a direct interaction. It preferentially binds to Mcl-1 and A1, but not to Bcl-2 or BclxL, to neutralize their anti-apoptotic effects [13] . In addition, Noxa might also regulate Mcl-1 protein stability [34, 35] since Noxa expression inversely correlated with Mcl-1 protein levels in some studies [36, 37] . In contrast, in our cell system, silencing of Noxa did not increase
Mcl-1 expression levels arguing against a role of Noxa for Mcl-1 degradation in our system.
Furthermore, it seems that binding of Noxa is not sufficient to induce apoptosis suggesting an additional signal that facilitates Mcl-1 downregulation and successive apoptosis.
Effects of Bcl-xL and Bcl-2
In cells overexpressing Bcl-2 or Bcl-xL RNAi-mediated downregulation of Mcl-1 was no longer sufficient to efficiently trigger apoptosis. Thus, Bcl-2 and Bcl-xL can substitute for groups [9, 11] . Since overexpression of Bcl-2 hardly affected Celecoxib-induced apoptosis, the sequestration of BH3-only Bim or tBid by anti-apoptotic proteins seems to be of minor importance. We, therefore, favor the indirect activation model in our Jurkat cell system as described earlier [8, 13, 37, 39] . In this scenario, Bcl-xL would exert its protection through interaction with Bak. Binding of BH3-only proteins to Bcl-xL would be required to displace
Bak from Bcl-xL to allow its activation. However, additional Celecoxib-dependent mechanisms could not be excluded. The activation of other BH3-only proteins acting directly on Bcl-xL and Bak is likely, but further experiments are needed to identify putative regulators. Pharmacia Pfizer kindly provided Celecoxib for our study.
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